

Rebecca Brown

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3635765/rebecca-brown-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

2,191
citations

27
h-index

46
g-index

70
ext. papers

2,653
ext. citations

6.5
avg, IF

5.07
L-index

#	Paper	IF	Citations
65	Apolipoprotein CIII and Angiotensin-like Protein 8 are Elevated in Lipodystrophy and Decrease after Metreleptin. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvaa191	0.4	3
64	Rare case of rectosigmoid stricture causing transverse colon volvulus. <i>BMJ Case Reports</i> , 2021 , 14,	0.9	
63	Energy expenditure due to gluconeogenesis in pathological conditions of insulin resistance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2021 , 321, E795-E801	6	1
62	Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e2953-e2967	5.6	4
61	Ovarian Hyperandrogenism and Response to Gonadotropin-releasing Hormone Analogues in Primary Severe Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 2367-2383	5.6	4
60	Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4163-e4178	5.6	1
59	Complement Factor D (adipsin) Levels Are Elevated in Acquired Partial Lipodystrophy (Barraquer-Simons syndrome). <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
58	Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e4327-e4339	5.6	4
57	Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy. <i>Journal of the Endocrine Society</i> , 2021 , 5, bvab019	0.4	8
56	Finding a sweet spot for leptin.. <i>Med</i> , 2021 , 2, 794-796	31.7	
55	Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use. <i>Current Medical Research and Opinion</i> , 2021 , 37, 1881-1889	2.5	1
54	Diagnostic Value of Anthropometric Measurements for Familial Partial Lipodystrophy, Dunnigan Variety. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	4
53	Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy. <i>Journal of the Endocrine Society</i> , 2020 , 4, bvz022	0.4	8
52	Leptin decreases de novo lipogenesis in patients with lipodystrophy. <i>JCI Insight</i> , 2020 , 5,	9.9	17
51	Free fatty acid processing diverges in human pathologic insulin resistance conditions. <i>Journal of Clinical Investigation</i> , 2020 , 130, 3592-3602	15.9	14
50	Thyroid Hormone Effects on Glucose Disposal in Patients With Insulin Receptor Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	6
49	Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile That Improves After Metreleptin in Patients with Lipodystrophy. <i>Journal of the Endocrine Society</i> , 2019 , 3, 1503-1517	0.4	12

48	Effects of metreleptin on proteinuria in patients with lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 ,	5.6	7
47	Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5120-5135	5.6	15
46	Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 3068-3076	5.6	12
45	Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 2216-2228	5.6	5
44	Visceral fat does not contribute to metabolic disease in lipodystrophy. <i>Obesity Science and Practice</i> , 2019 , 5, 75-82	2.6	1
43	Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy. <i>Endocrine</i> , 2019 , 64, 500-511	4	37
42	Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy. <i>Endocrine</i> , 2018 , 60, 479-489	4	42
41	Contribution of Adipose-Derived Factor D/Adipsin to Complement Alternative Pathway Activation: Lessons from Lipodystrophy. <i>Journal of Immunology</i> , 2018 , 200, 2786-2797	5.3	33
40	Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy. <i>Journal of Clinical Investigation</i> , 2018 , 128, 3504-3516	15.9	60
39	Effect of Leptin Replacement Therapy (LRT) on Survival and Disease Progression in Generalized and Partial Lipodystrophy (GL, PL). <i>Diabetes</i> , 2018 , 67, 106-LB	0.9	2
38	Patient Quality of Life and Benefits of Leptin Replacement Therapy (LRT) in Generalized and Partial Lipodystrophy (GL, PL). <i>Diabetes</i> , 2018 , 67, 1331-P	0.9	1
37	Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study. <i>Diabetes Care</i> , 2018 , 41, 2353-2360	14.6	13
36	Genetics of Lipodystrophy. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017 , 46, 539-554	5.5	30
35	Effects of Metreleptin in Pediatric Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1511-1519	5.6	31
34	Metreleptin therapy lowers plasma angiotensin-like protein 3 in patients with generalized lipodystrophy. <i>Journal of Clinical Lipidology</i> , 2017 , 11, 543-550	4.9	14
33	Clinical Features and Management of Non-HIV-Related Lipodystrophy in Children: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 363-374	5.6	29
32	Type B Insulin Resistance Masquerading as Ovarian Hyperthecosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1789-1791	5.6	13
31	Lymphoma in acquired generalized lipodystrophy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 45-50	1.9	23

30	Hormonal responses to non-nutritive sweeteners in water and diet soda. <i>Nutrition and Metabolism</i> , 2016 , 13, 71	4.6	52
29	Other Antibodies Resulting in Diabetes Mellitus: Type B Insulin Resistance and Insulin Autoimmune Syndrome. <i>AACE Clinical Case Reports</i> , 2016 , 2, e274-e275	0.7	1
28	Management of Diabetic Ketoacidosis in Severe Insulin Resistance. <i>Diabetes Care</i> , 2016 , 39, e116-8	14.6	3
27	Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 59-68	3.8	38
26	Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy. <i>Clinical Endocrinology</i> , 2016 , 85, 137-49	3.4	29
25	Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients. <i>Endocrinology</i> , 2016 , 157, 1421-9	4.8	14
24	Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1790-7	5.6	8
23	The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 4500-4511	5.6	205
22	Leptin Does Not Mediate Hypertension Associated With Human Obesity. <i>Cell</i> , 2015 , 162, 465-6	56.2	32
21	Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 1802-10	5.6	97
20	Lipid regulation in lipodystrophy versus the obesity-associated metabolic syndrome: the dissociation of HDL-C and triglycerides. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1676-80	5.6	24
19	Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 8901-6	11.5	88
18	Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1493-500	5.6	30
17	Effects of leptin replacement therapy on pancreatic β cell function in patients with lipodystrophy. <i>Diabetes Care</i> , 2014 , 37, 1101-7	14.6	18
16	The liver diseases of lipodystrophy: the long-term effect of leptin treatment. <i>Journal of Hepatology</i> , 2013 , 59, 131-7	13.4	118
15	Metreleptin improves blood glucose in patients with insulin receptor mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, E1749-56	5.6	24
14	The clinical approach to the detection of lipodystrophy - an AACE consensus statement. <i>Endocrine Practice</i> , 2013 , 19, 107-16	3.2	64
13	Low-calorie sweetener consumption is increasing in the United States. <i>American Journal of Clinical Nutrition</i> , 2012 , 96, 640-6	7	143

12	Non-nutritive sweeteners and their role in the gastrointestinal tract. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2597-605	5.6	73
11	The use of low-calorie sweeteners by children: implications for weight management. <i>Journal of Nutrition</i> , 2012 , 142, 1155S-62S	4.1	33
10	Effects of diet soda on gut hormones in youths with diabetes. <i>Diabetes Care</i> , 2012 , 35, 959-64	14.6	68
9	Consequences of stopping and restarting leptin in an adolescent with lipodystrophy. <i>Hormone Research in Paediatrics</i> , 2012 , 78, 320-5	3.3	16
8	Artificial sweetener use among children: epidemiology, recommendations, metabolic outcomes, and future directions. <i>Pediatric Clinics of North America</i> , 2011 , 58, 1467-80, xi	3.6	49
7	Clinical trials in youth with type 2 diabetes. <i>Pediatric Diabetes</i> , 2011 , 12, 50-7	3.6	10
6	Cushing syndrome in the McCune-Albright syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 1508-15	5.6	92
5	Type 1 and Type 2 Diabetes in Five Race and Ethnic Populations: the SEARCH for Diabetes in Youth Study. <i>Current Cardiovascular Risk Reports</i> , 2010 , 4, 175-177	0.9	1
4	Artificial sweeteners: a systematic review of metabolic effects in youth. <i>Pediatric Obesity</i> , 2010 , 5, 305-12		142
3	Ingestion of diet soda before a glucose load augments glucagon-like peptide-1 secretion. <i>Diabetes Care</i> , 2009 , 32, 2184-6	14.6	122
2	Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data. <i>Pediatric Diabetes</i> , 2008 , 9, 14-22	3.6	68
1	Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. <i>Diabetes Care</i> , 2008 , 31, 1403-4	14.6	70